Abstract
Introduction
As per GLOBOCAN 2018, lung cancer is the most common cancer in the world at 11.6% and has the highest mortality. In India it is the fourth most common cancer comprising of 5.9% of all the new cases and is responsible for 9.3 % of all cancer related mortality in both sexes.1 As in developing countries most of the patients present in locally advanced stages. The overall 5-year survival rate of lung cancer is dismal with approximately 15 per cent in developed countries and 5 per cent in developing countries.2 In the department of Radiotherapy PGIMS, Rohtak carcinoma lung constituted 8.1 % of all the cancer patients registered of which less than 1 % are early stage.3 Surgery is the standard mode of treatment of patients with stage I and II tumors and for selective patients with stage III tumors. But only 20% of all the patients presenting with lung cancer are suitable for surgery.4Conventional fractionated radiotherapy is recommended, with reported 5-year local control and overall survival rates ranging from 30% to 50% and 10% to 30% respectively in stage I/II Non-Small cell lung carcinoma.5
References
- Ferlay J, Soeriomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2018 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France International Agency for Research on Cancer; 2018.
- Parkin DM, Bray F. Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cncer J Clin. 2005;55:74-108
- B. D. Sharma PGIMS, Rohtak (India). Data for the year 2017. Retrieved in January 2018 from Radiotherapy OPD record section.
- Pearson FG. Current status of surgical resection for lung cancer. Chest 1997;106:337.
- Singh N, Aggarwal AN, Gupta D, Behera D, Jindal SK. Unchanging clinic-epidemiological profile of lung cancer in North India over three decades. Cancer Epidemiol. 2009;10:1033-4
- Yamanashi K, Okumura N, Takahashi A, Nakashima T, Matsuoka T. Surgical andsurvival outcomes of lung cancer patients with intratumoral lung abscesses. JCardiothorac Surg. 2017 May 26;12(1):44.
- Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111(6):1710–1717
- Pairolero PC, Williams DE, Bergstralh EJ, et al. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg. 1984;38(4):331–338.
- Feld R, Rubinstein LV, Weisenberger TH. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J ClinOncol. 1984;2(12):1352–1358.
- Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J ThoracOncol. 2007;2(8):706–714.
- Scott WJ, Howington J, Feigenberg S, et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition) Chest. 2007;132(3 Suppl):234S–242S.
- Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
- Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60(3):615–622. discussion 622-3.
- Wang HH, Deng L, Wen QL, et al. Early postoperative radiotherapy is associated with improved outcomesover late postoperative radiotherapy in the management of completely resected(R0) Stage IIIA-N2 non-small cell lung cancer. Oncotarget. 2017 May23;8(38):62998-63013.
Corresponding Author
Dr Joydeep Singh Vasant
3rd year PG student, Department of Radiotherapy, PGIMS, Rohtak, India
DOI: https://dx.doi.org/10.18535/jmscr/v7i3.66
